Cargando…

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease

To assess the discriminating power of multiple cerebrospinal fluid (CSF) biomarkers for Parkinson's disease (PD), we measured several proteins playing an important role in the disease pathogenesis. The activities of β-glucocerebrosidase and other lysosomal enzymes, together with total and oligo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parnetti, Lucilla, Chiasserini, Davide, Persichetti, Emanuele, Eusebi, Paolo, Varghese, Shiji, Qureshi, Mohammad M, Dardis, Andrea, Deganuto, Marta, De Carlo, Claudia, Castrioto, Anna, Balducci, Chiara, Paciotti, Silvia, Tambasco, Nicola, Bembi, Bruno, Bonanni, Laura, Onofrj, Marco, Rossi, Aroldo, Beccari, Tommaso, El-Agnaf, Omar, Calabresi, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282452/ https://www.ncbi.nlm.nih.gov/pubmed/24436092 http://dx.doi.org/10.1002/mds.25772

Ejemplares similares

Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid
por: Persichetti, Emanuele, et al.
Publicado: (2014)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies
por: Chiasserini, Davide, et al.
Publicado: (2015)

Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson’s disease: protocol for a systematic review and individual participant data meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2017)

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
por: Majbour, Nour K., et al.
Publicado: (2017)

Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2016)

Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson’s Disease
por: Paciotti, Silvia, et al.
Publicado: (2020)

Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies
por: Moors, Tim E., et al.
Publicado: (2018)

Entacapone Reduces Cortical Activation in Parkinson's Disease with Wearing-Off: A f-MRI Study
por: Tambasco, Nicola, et al.
Publicado: (2014)

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia
por: Chiasserini, Davide, et al.
Publicado: (2017)

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
por: Eusebi, Paolo, et al.
Publicado: (2018)

Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of “Protein-Misfolding Cyclic Amplification” and “Real-Time Quaking-Induced Conversion” as Diagnostic Tools
por: Paciotti, Silvia, et al.
Publicado: (2018)

Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
por: Bellomo, Giovanni, et al.
Publicado: (2020)

Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation
por: Wojdała, Anna Lidia, et al.
Publicado: (2022)

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
por: Cicognola, Claudia, et al.
Publicado: (2016)

Immunological Profile of Silent Brain Infarction and Lacunar Stroke
por: Sarchielli, Paola, et al.
Publicado: (2013)

Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Issue of Diurnal Variation
por: Cicognola, Claudia, et al.
Publicado: (2015)

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
por: Sjödin, Simon, et al.
Publicado: (2019)

Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

Neuro-Immune Cross-Talk in the Striatum: From Basal Ganglia Physiology to Circuit Dysfunction
por: Mancini, Andrea, et al.
Publicado: (2021)

Clinical Aspects and Management of Levodopa-Induced Dyskinesia
por: Tambasco, Nicola, et al.
Publicado: (2012)

Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies()
por: Bonanni, Laura, et al.
Publicado: (2015)

Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays
por: Bellomo, Giovanni, et al.
Publicado: (2023)

Incidence and Antiseizure Medications of Post-stroke Epilepsy in Umbria: A Population-Based Study Using Healthcare Administrative Databases
por: Costa, Cinzia, et al.
Publicado: (2022)

Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
por: Bellomo, Giovanni, et al.
Publicado: (2021)

Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer’s disease continuum
por: Paciotti, Silvia, et al.
Publicado: (2023)

A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation
por: Gaetani, Lorenzo, et al.
Publicado: (2018)

Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis
por: Parnetti, Lucilla, et al.
Publicado: (2019)

Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies
por: Tambasco, Nicola, et al.
Publicado: (2021)

Glycogen Reduction in Myotubes of Late-Onset Pompe Disease Patients Using Antisense Technology
por: Goina, Elisa, et al.
Publicado: (2017)

Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration
por: Ghiglieri, Veronica, et al.
Publicado: (2018)

Complexity of Motor Sequences and Cortical Reorganization in Parkinson's Disease: A Functional MRI Study
por: Caproni, Stefano, et al.
Publicado: (2013)

The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase
por: Fog, Cathrine K., et al.
Publicado: (2018)

Levodopa in Parkinson’s Disease: Current Status and Future Developments
por: Tambasco, Nicola, et al.
Publicado: (2018)

α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers
por: Gorostidi, Ana, et al.
Publicado: (2012)

Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers
por: Barba, Lorenzo, et al.
Publicado: (2022)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Profile of eliglustat tartrate in the management of Gaucher disease
por: Sechi, Annalisa, et al.
Publicado: (2016)

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
por: Aasly, Jan O., et al.
Publicado: (2014)

Advances in understanding the function of alpha-synuclein: implications for Parkinson’s disease
por: Calabresi, Paolo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p091mdj7pi9vdoomuc8j09fl0e